Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.86)
# 371
Out of 5,053 analysts
236
Total ratings
56.1%
Success rate
32%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Downgraded: Hold | $18 → $3 | $1.85 | +62.16% | 3 | Oct 13, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $138 → $146 | $79.62 | +83.37% | 20 | Oct 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $65 → $70 | $31.68 | +120.96% | 2 | Oct 13, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,059 → $1,078 | $802.64 | +34.31% | 14 | Oct 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Hold | $16 → $18 | $14.92 | +20.64% | 7 | Sep 21, 2026 | |
| ABBV AbbVie | Rated: Buy | $235 → $260 | $274.36 | -5.23% | 18 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $11.14 | +88.51% | 6 | Aug 10, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | $120 → $134 | $77.58 | +72.72% | 10 | Aug 10, 2026 | |
| EVMN Evommune | Reiterated: Buy | $55 → $22 | $5.88 | +274.15% | 4 | Aug 10, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Hold | $19 | $16.51 | +15.08% | 28 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $39 → $5 | $1.60 | +212.50% | 2 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 → $78 | $51.80 | +50.58% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $18.22 | +42.70% | 12 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $329 | $223.21 | +47.39% | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $162 → $170 | $96.79 | +75.64% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $15.30 | +115.69% | 7 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $91 | $26.79 | +239.68% | 8 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4956 | - | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.72 | - | 7 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $23.74 | +114.83% | 1 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $295 → $300 | $321.16 | -6.59% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $9.94 | +81.09% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $18.56 | +147.84% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $26 | $34.38 | -24.37% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $8.07 | +110.66% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.69 | +136.69% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.48 | +237.84% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $2.30 | +117.39% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.16 | +246.32% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.78 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $108.62 | n/a | 1 | Aug 3, 2022 |
Foghorn Therapeutics
Oct 13, 2026
Downgraded: Hold
Price Target: $18 → $3
Current: $1.85
Upside: +62.16%
Mirum Pharmaceuticals
Oct 13, 2026
Reiterated: Buy
Price Target: $138 → $146
Current: $79.62
Upside: +83.37%
First Tracks Biotherapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $65 → $70
Current: $31.68
Upside: +120.96%
argenx SE
Oct 9, 2026
Reiterated: Buy
Price Target: $1,059 → $1,078
Current: $802.64
Upside: +34.31%
Ultragenyx Pharmaceutical
Sep 21, 2026
Reiterated: Hold
Price Target: $16 → $18
Current: $14.92
Upside: +20.64%
AbbVie
Aug 10, 2026
Rated: Buy
Price Target: $235 → $260
Current: $274.36
Upside: -5.23%
COMPASS Pathways
Aug 10, 2026
Reiterated: Buy
Price Target: $21
Current: $11.14
Upside: +88.51%
Dianthus Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $120 → $134
Current: $77.58
Upside: +72.72%
Evommune
Aug 10, 2026
Reiterated: Buy
Price Target: $55 → $22
Current: $5.88
Upside: +274.15%
Sarepta Therapeutics
Aug 10, 2026
Reiterated: Hold
Price Target: $19
Current: $16.51
Upside: +15.08%
Aug 10, 2026
Downgraded: Hold
Price Target: $39 → $5
Current: $1.60
Upside: +212.50%
Aug 10, 2026
Reiterated: Buy
Price Target: $68 → $78
Current: $51.80
Upside: +50.58%
Aug 10, 2026
Reiterated: Buy
Price Target: $26
Current: $18.22
Upside: +42.70%
Aug 7, 2026
Reiterated: Buy
Price Target: $329
Current: $223.21
Upside: +47.39%
Aug 7, 2026
Reiterated: Buy
Price Target: $162 → $170
Current: $96.79
Upside: +75.64%
Jul 27, 2026
Reiterated: Buy
Price Target: $33
Current: $15.30
Upside: +115.69%
Jul 9, 2026
Reiterated: Buy
Price Target: $91
Current: $26.79
Upside: +239.68%
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.4956
Upside: -
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $16.72
Upside: -
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $23.74
Upside: +114.83%
May 5, 2026
Reiterated: Buy
Price Target: $295 → $300
Current: $321.16
Upside: -6.59%
Apr 1, 2026
Reiterated: Buy
Price Target: $20 → $18
Current: $9.94
Upside: +81.09%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $18.56
Upside: +147.84%
Mar 2, 2026
Reiterated: Buy
Price Target: $24 → $26
Current: $34.38
Upside: -24.37%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $8.07
Upside: +110.66%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $1.69
Upside: +136.69%
Dec 17, 2025
Reiterated: Buy
Price Target: $5
Current: $1.48
Upside: +237.84%
Dec 17, 2025
Reiterated: Hold
Price Target: $5
Current: $2.30
Upside: +117.39%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $1.16
Upside: +246.32%
May 30, 2023
Reiterated: Buy
Price Target: $10
Current: $2.78
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $108.62
Upside: n/a